|
|
|
| Meta analysis of the clinical efficacy of antiviral combined with TACE in the treatment of hepatitis B virus associated hepatocellular cancer |
| CHEN Huihua WEN Lingbo LI Jian′an JIA Yanhua |
| Department of Oncology, the Second Affiliated Hospital of Guangxi University of Science and Technology, Guangxi Zhuang Autonomous Region, Liuzhou 545006, China |
|
|
|
|
Abstract Objective To evaluate the clinical efficacy of antiviral combined with transarterial chemoembolization (TACE) in the treatment of hepatitis B virus associated hepatocellular cancer. Methods The following databases such as CNKI, Wanfang Date, VIP, PubMed, The Cochrane Library, Embase were retrieved from the time of the database established to April 30, 2017.Randomized controlled clinical trials (RCTs) that antiviral combined with transarterial chemoembolization in the treatment of hepatitis B virus associated hepatocellular cancer were included, the Jadad score method was used to carryout quality assessment. Meta-analysis was conducted by RevMan 5.2 software. Results A total of 275 papers were searched. Finally 10 references, 844 patients were included in the Meta analysis. Meta analysis results showed that the Antiviral combined with TACE in the treatment of patients with hepatitis B related hepatocellular cancer in the near future clinical efficacy (OR=2.47, 95%CI:1.54-3.95,P=0.0002), ALT improve condition (OR=-34.23, 95%CI:-46.24--22.21, P < 0.00001), HBV DNA quantitative improve condition (OR=-2.91, 95%CI:-4.16--1.67,P <0.00001), AFP improve condition (OR=-33.86, 95%CI:-37.91--29.82,P < 0.00001) were better than simple TACE treatment. There were no significant differences between two groups in 1-year survival rate (OR=1.94, 95%CI:0.89-4.22,P=0.09). Conclusion Antiviral combined with TACE is superior to simple TACE in the treatment of hepatitis B related liver cancer, which is worthy of clinical recommendation.
|
|
|
|
|
|
[1] El-Serag HB. Hepatocellular carcinoma [J]. N Engl J Med，2011，365（12）：1118-1127.
[2] 杨广辉，刘立民，韩正祥，等.经导管肝动脉化疗栓塞联合经皮穿刺微波凝固治疗对原发性肝癌患者Th22细胞数量和功能的影响[J].中华消化病与影像杂志：电子版，2015，5（2）：81-85.
[3] 张呈，陈昌南，林云笑，等.替吉奥联合经肝动脉化疗栓塞治疗中晚期肝细胞癌的疗效观察[J].临床肝胆病杂志，2014，30（1）：55-57.
[4] Huang G，Lai ECH，Lau WY，et al. Posthepatectomy HBV reactivation in Hepatitis B-related hepatocellular carcinoma influences postoperative survival in patients with preoperative low HBV-DNA levels [J]. Ann Surg，2013，257（3）：490-505.
[5] Moher D，Pham B，Jones A，et al. Does quality of reports of randomizedtrials affect estimates of intervention efficacy reported in meta-analyses [J]. Lancet，1998，3（52）：609-613.
[6] Dawey SG，Egger M. Meta-analyses of randomised controlled trials [J]. Lancet，1997，350（9085）：1182.
[7] Mantel N，Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease [J]. J Natl Cancer Inst，1959，22（4）：719-748.
[8] DerSimonian R，Laird N. Meta-analysis in clinical trials[J]. Control Clin Trials，1986，7（3）：177-188.
[9] 郭宏华，晁阳，李岩，等.抗病毒治疗对乙型肝炎相关原发性肝癌临床疗效的影响[J].中国老年学杂志，2011，31（16）：3016-3018.
[10] 轩杰，马生录，唐江燕，等.恩替卡韦联合肝动脉化疗栓塞术治疗乙型肝炎相关中晚期肝癌患者的疗效观察[J].宁夏医学杂志，2013，35（10）：947-948.
[11] 王满，赵立群，徐峰，等.抗病毒治疗对经肝动脉化疗栓塞乙肝相关原发性肝癌的作用[J].实用医学杂志，2014， 30（22）：3620-3621.
[12] 郭锰.恩替卡韦联合介入治疗乙型肝炎相关原发性肝癌的临床研究[J].中国普通外科杂志，2014，23（7）：898-903.
[13] 谢湘平.抗病毒治疗乙型肝炎相关原发性肝癌患者临床疗效观察[J].海峡药学，2016，28（8）：173-174.
[14] 吴菊意.恩替卡韦联合介入治疗乙型肝炎相关原发性肝癌临床效果观察[J].中国实用医药，2016，11（16）：173-174.
[15] 杨阳，杨龙，魏燕，等.抗病毒联合TACE治疗乙肝病毒阴性肝癌的临床研究[J].中华肿瘤防治杂志，2016，23（1）：25-29.
[16] 王丽君，卜文哲，陈华，等.TACE联合恩替卡韦治疗乙型肝炎相关原发性肝癌回顾性分析[J].中华肿瘤防治杂志，2014，21（20）：1617-1622.
[17] 王忠，刘启榆，杨伟，等.介入治疗联合抗病毒治疗乙肝相关肝癌的疗效分析[J].中华肿瘤防治杂志，2016，23（S1）：158-159.
[18] 胡兴龙，王胜智，康志龙，等.乙型肝炎继发肝癌患者TACE术围术期使用恩替卡韦的临床观察[J].中国药房，2017，28（2）：246-249.
[19] Zhong JH，Xiang BD，Gong WF，et al. Comparison of long-term survival of patients with BCLC stage B hepatocellular carcinoma after liver resection or transarterial chemoembolization [J]. Plos One，2013，8（7）：e68183.
[20] Shaikh T，Cooper C. Reassessing the role for lamivudine in choronichepatitis B infection：a four-year cohort analysis [J]. Can J Gastroenterol，2012，26（3）：148-150. |
|
|
|
